One of the strengths of our program is our ability to accurately diagnose bone marrow failure syndromes, which can mimic many other conditions. For our diagnostic skills and in-depth research program in these diseases, the MDS Foundation has designated Memorial Sloan-Kettering a Center of Excellence.
Because of their complexity, bone marrow failure syndromes require a carefully-thought-out, evolving care plan. One of my goals is to educate and empower my patients so they can participate fully in decision-making about their care. I also encourage patients to participate in clinical trials, because we need more and better treatments. For example, currently there are only three FDA-approved treatments for MDS.
I am an investigator on many clinical trials that will hopefully lead to the development of new treatments for people with MDS and leukemia. I am particularly interested in “epigenetic” therapies, which restore the ability of bone marrow cells to use genetic information needed to make blood cells. In addition, I collaborate extensively with laboratory scientists both within Memorial Sloan-Kettering and at other institutions to learn more about the blood and bone marrow abnormalities in patients with these diseases. We then use those new discoveries to develop new treatments. I am an author of numerous manuscripts describing clinical trials, including those that led to FDA approval of treatments for MDS.